This presentation contains forward-looking statements, including statements related to: our financial outlook and other financial performance; the process and timing of anticipated future clinical development of our product candidates; our business strategy, goals, plans and prospects; timing and outcome of our clinical trials; our ability to obtain regulatory approval; the potential therapeutic and economic benefits and value of our product candidates; potential benefits of our product candidates and our technologies; demand for our product candidates and drivers of demand; market size, adoption rate and potential revenue; growth opportunities and product pipeline; our ability to leverage our investment in our development and manufacturing platform; and our intellectual property strategy.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design; our ability to obtain and maintain regulatory approval of our product candidates; our ability to obtain funding for our operations; our plans to research, develop and commercialize our product candidates; our ability to achieve market acceptance of our product candidates; unanticipated costs or delays in research, development and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our product candidates; our ability to successfully commercialize our product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; and our ability to continue obtaining and maintaining intellectual property protection for our product candidates. These and other risks are described in the “Risk Factors” section of our Form 10-Q filed with the Securities and Exchange Commission on May 14, 2015. The “Risk Factors” section of 10-Q speaks only as of the date thereof. These forward-looking statements speak only as of the date hereof or the date specified. Revance disclaims any obligation to update these forward-looking statements.

“Revance Therapeutics”, TransMTS® and the Revance logo are registered trademarks of Revance Therapeutics, Inc. All other trademarks or registered trademarks are the property of their respective owners.
Our vision is to revolutionize the standard of care for patients by commercializing next-generation botulinum toxin and other therapies with our unique delivery platform.
INVESTMENT HIGHLIGHTS

UNIQUE, PATENTED TECHNOLOGY
Enables Macromolecule Delivery of Toxin; Enhances Penetration

LARGE ADDRESSABLE MARKETS
$3.0 Billion in 2014, Growing to nearly $5.6 Billion in 2020

TWO DRUG CANDIDATES, MULTIPLE INDICATION OPTIONS
RT001 – Topical Botulinum Toxin Type A
RT002 – Injectable Botulinum Toxin Type A

DIVERSIFIED CLINICAL PORTFOLIO
AESTHETICS
Phase 3 – RT001 for Crow’s Feet Lines*
Phase 2 – RT002 for Glabellar (Frown) Lines

THERAPEUTICS
Phase 2 – RT001 for Hyperhidrosis (Excessive Sweating)*
Phase 2 – RT002 for Cervical Dystonia*

* To be initiated 2H ’15
Patented Macromolecule Transport Technology

Potential to transform the way botulinum toxin is delivered and improve the customer experience.

TransMTS® Peptide
Highly Charged Peptide Binds Non-Covalently to Target

RT001 - TOPICAL
Enable Macromolecule Delivery

RT002 - INJECTABLE
Deeper Targets

OTHER ACTIVES
Enhance Penetration
Botulinum Toxin Market - $3B and Growing

Global Neurotoxin Revenue Growth

**ACROSS INDICATIONS**

- **2014E**
  - $3.0B
  - Therapeutic
  - Cosmetic

- **2020E**
  - $5.6B
  - CAGR 10%

**ACROSS GEOGRAPHIES**

- **2014E**
  - $3.0B
  - US
  - EU
  - ROW

- **2020E**
  - $5.6B
  - CAGR 13%
  - CAGR 12%
  - CAGR 10.5%

# Rich Pipeline with Multiple Indications

<table>
<thead>
<tr>
<th>PIPELINE</th>
<th>PRE-Clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RT001 TOPICAL PRODUCT CANDIDATE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lateral Canthal Lines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Crow's Feet)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyperhidrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Excessive Sweating)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Therapeutic Indications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>RT002 INJECTABLE PRODUCT CANDIDATE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glabellar (Frown) Lines</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical Dystonia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Therapeutic Indications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
RT001 – Topical Gel Product Candidate

For **mid-dermal** delivery of botulinum toxin to provide a **topical alternative to the injectable products** on the market today.

**POTENTIAL AESTHETIC OPTIONS**
- Crow’s Feet Lines
- Forehead
- Above the Lip
- Neck/Décolletage

**POTENTIAL THERAPEUTIC OPTIONS**
- Excessive Sweating
- Migraines
- Shingles
- Anal Fissures

Designed to offer consumers a safe, natural-looking aesthetic result with no needles, no down time, no bruising, and no pain.
RT001 Topical - Crow’s Feet Lines
Easy to Use, Not Technique Dependent

1. Prepare Applicator
   - Proprietary Dispenser
     Minimizes Misuse
   - Simple to Use

2. Apply Gel to Crow’s Feet
   - Viscous Gel: Stays at Target

3. Dwell Time/Removal
   - 30 Minutes Fits into Current Practice Office Flow
   - Gel Easily Removed with Proprietary Cleansing Step
RT001 Topical - Crow’s Feet Lines May Address Barriers to Adoption

**APPEARANCE / CONCERNS**

**FEAR OF “FROZEN FACE”**

- Relax Wrinkles at Rest
- Maintain “Natural” Look vs. Frozen Face
- Keeps Expression, Eliminate Wrinkles
- Desire for Natural Look

**NO NEEDLES**

**“I DON’T LIKE NEEDLES”**

- Topically Applied
- No Injections
- No Pain
- No Bruising or Swelling

**PERCEIVED SAFER**

**“POISONS ARE SCARY”**

- Topical Makes It Seem Less “Toxic”
- 54% of Consumers Who Did Not Want a BoNTA Injection Would Chose RT001 Concept
- Injected IN the Body Is Different from ON the Skin

**“BOTOX* freezes your expression, whereas RT001 softens them”**

**“All things being equal, everyone would prefer a cream”**

*Better than BOTOX* – not injected into your body”

“[not good] to have foreign chemicals injected into your skin, so RT001 is definitely better”

Source: Primary Quantitative Research Conducted by GfK Healthcare, 2012
Sample size of 630 female consumers
MAJORITY OF US WOMEN REMAIN ON THE SIDELINES

US Market in 2012

51M
Women 30+ (HHI>$50K)

27M
Considering Treatments

6.6M
Considering BoNTA Injections

1.8M
Female Users

Only 7% of Women Actively Considering Treatments Have Had BoNTA Injections

Source: Primary Quantitative Research Conducted by GfK Healthcare, 2012
Sample size of 630 female consumers
RT001 Topical – Crow’s Feet Lines
Next Steps

- Initiate US Phase 3 Pivotal Study – 2H 2015
  - Randomized, double-blind, placebo-controlled, multi-center study
  - Safety and efficacy of a single topical application
  - Adults with moderate to severe lateral canthal (crow’s feet) lines
  - Same clinical endpoints as Phase 2b

- Advancing clinical methods, such as such as electromyography (EMG), to directly measure and assess paralytic effect
RT001 Topical - Hyperhidrosis (Excessive Sweating)
Significant Unmet Need

- **9M sufferers in the US**
  - More than 50% of sufferers are not diagnosed or treated
  - 1.6m rate sweating as intolerable
  - Significant lifestyle changes needed to manage condition, with dramatic and pervasive impact on quality of life

- **Opportunity with consumers who believe they sweat too much**
  - More than 1/3 of US adults
  - 60% are embarrassed by sweating
  - Only 38% of sufferers have spoken to a physician about the condition

RT001 Topical - Hyperhidrosis (Excessive Sweating)
Designed to offer a topical, painless treatment

Prior proof-of-concept study

- As the dose of RT001 increased, primary and secondary endpoints exhibited increased signal
- Strong safety profile
  - All AE’s were mild or moderate and transient
  - All doses were well-tolerated

US Phase 2 study to be initiated 2H 2015

- Randomized, dose-ranging, placebo-controlled, multiple site study
- Safety and efficacy of a single application
- Moderate to severe hyperhidrosis
RT002 Next Generation Injectable Botulinum Toxin Product Candidate

Designed to provide a **deeper, more targeted delivery** of botulinum toxin to intended treatment sites while **reducing the spread** beyond the site of local injection. Potential to result in a **longer-lasting effect**

**POTENTIAL AESTHETIC OPTIONS**
- Glabellar (Frown) Lines
- Eye Brow
- Masseter (Face Shaping)
- Platysmal Bands

**POTENTIAL THERAPEUTIC OPTIONS**
- Cervical Dystonia
- Upper Limb Spasticity
- Overactive Bladder
- TMJ/Teeth Grinding
- Back Pain
- Benign Prostatic Hyperplasia
RT002 Injectable - Phase 1/2 Study for Glabellar (Frown) Lines - Published in Dermatologic Surgery, Jan 2015

**COHORT 1 (Lowest Dose) – Treatment Example**

**Objective**
- Safety and efficacy of RT002 in glabellar lines

**Study Design**
- Open-label, dose escalating; 4 cohorts

**Efficacy Measures – Consistent with literature on Approved Injectables**

**RT002 appears to be safe and well tolerated**
- No evidence of spread beyond treatment site
- AE’s were generally mild, localized and transient
- No evidence of any systemic exposure

**GLABELLAR LINE SEVERITY SCALE AT MAXIMUM FROWN AT WEEK 4 (% Responders)**

<table>
<thead>
<tr>
<th>Patients with None/Mild</th>
<th>1-Point</th>
<th>2-Point</th>
</tr>
</thead>
<tbody>
<tr>
<td>96%</td>
<td>98%</td>
<td>67%</td>
</tr>
</tbody>
</table>

N=48

* Photos provided by physician; not included in the duration cohort
RT002 Injectable – Frown Lines Demonstrates Duration of 7 Months

**Subject Assessment**
- Duration of effect back to baseline was 29.4 weeks based on both investigator and subject assessments.
- At the 6 month time-point 80% of subjects maintained at least 1-point improvement.
- 60% demonstrated None/Mild wrinkles.

**Investigator Assessment**
- Subjects with GLSS score < baseline GLSS score (%): Median duration of response = 29.4 weeks.
RT002 Treatment Example
Cohort 4 - Baseline and Week 24

SINGLE TREATMENT – COHORT 4

Baseline
Week 24

SUBJECT RT002-1010
**RT002: Longer Duration = Meaningful Differentiation**
Qualitative Market Research Among Thought-Leaders

**OBJECTIVE/METHODOLOGY**

- Determine appeal of RT002 product concept among clinician thought-leaders
  - Expose clinicians to the RT002 product concept in a focus group and 1:1 interviews
    - Over 30 specialists across all core specialties

**KEY LEARNINGS**

- Overall, clinicians were very impressed by the RT002 injectable data
  - Median duration of 29.4 weeks is a “game changer”
  - If RT002 was approved by the FDA with a meaningful increase in duration (6 months), **then they would switch** from their current injectable BoNTA

- Duration was the more meaningful benefit **“Duration trumps everything”**
  - Viewed duration as a key **unmet need**

- Consensus was that 6-7 months was the ideal duration of effect
  - Fits into current patient habits (most patients come in ≈ twice per year)
RT002 Injectable for Frown Lines
Phase 2 BELMONT Study Fully Enrolled

- Randomized, double-blind, dose-ranging, active and placebo controlled, multi-center study
- Comparator against the market leader, BOTOX* Cosmetic
- Five arms:
  - Three different doses of RT002 injectable
  - BOTOX* Cosmetic (comparator)
  - Placebo
- > 250 patients
- 24-week (~6 months) duration results expected in late 2015

*BOTOX® is a registered trademark of Allergan, Inc.
RT002 Injectable – Cervical Dystonia
Plan to Initiate Phase 2 Study in 2H, Report Results End of 2015

- Muscle movement disorders, including cervical dystonia, make up about half of the 2014E $1.7B neurotoxin therapeutic sales globally
  - Affects a person’s ability to control muscle activity, often due to nervous system damage caused by a stroke, disease, or trauma
  - Painful and significantly impacts quality of life
- Neurology has a targeted physician base easily accessed by specialty sales force

Cervical Dystonia
- Excessive pulling of the muscles in the neck and shoulder
- A condition where deeper, more targeted botulinum toxin delivery is required and longer duration is desired
- Clear, proven clinical and regulatory path for injectable toxin

Robust Intellectual Property

Botulinum Toxin Type A

Topical (RT001)  Injectable (RT002)

TransMTS® Composition  Indications  Methods of Manufacture  Applicator  Safe Disposal  Composition Of Matter  Methods of Manufacture  TransMTS® Composition

GRANTED/PENDING PATENTS

- 97 Issued Patents - US, EU, Latin America, Asia
- 151 Pending Patents Applications
- Core US composition and methods patents expire in 2027 and 2029
  - Potentially extendable for up to 5 years
**2015 Financial Guidance & Share Overview** *(millions)*

<table>
<thead>
<tr>
<th>FY 2015 NON-GAAP OPERATING EXP. GUIDANCE</th>
<th>$72 to $80 (Excluding D&amp;A and stock-based compensation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY 2015 CASH BURN GUIDANCE</td>
<td>$74 to $84</td>
</tr>
<tr>
<td>CASH – AS OF DEC. 31, 2014</td>
<td>$171</td>
</tr>
</tbody>
</table>

**2015 Guidance as of May 13, 2015**

<table>
<thead>
<tr>
<th>As of March 31, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>SHARES OUTSTANDING</td>
</tr>
<tr>
<td>WARRANTS OUTSTANDING</td>
</tr>
<tr>
<td>OPTIONS OUTSTANDING</td>
</tr>
<tr>
<td>FULLY DILUTED SHARES</td>
</tr>
<tr>
<td>MANAGEMENT/BOARD OWNERSHIP</td>
</tr>
</tbody>
</table>

* Includes restricted shares

** Excludes shares owned by funds managed by board members
Investment Highlights

**UNIQUE, PATENTED TECHNOLOGY**
Enables Macromolecule Delivery of Toxin; Enhances Penetration

**LARGE ADDRESSABLE MARKETS**
$3.0 Billion in 2014, Growing to nearly $5.6 Billion in 2020

**TWO DRUG CANDIDATES, MULTIPLE INDICATION OPTIONS**
RT001 – Topical Botulinum Toxin Type A
RT002 – Injectable Botulinum Toxin Type A

**DIVERSIFIED CLINICAL PORTFOLIO**

**AESTHETICS**
Phase 3 – RT001 for Crow’s Feet Lines*
Phase 2 – RT002 for Glabellar (Frown) Lines

**THERAPEUTICS**
Phase 2 – RT001 for Hyperhidrosis (Excessive Sweating)*
Phase 2 – RT002 for Cervical Dystonia*

* To be initiated 2H ‘15
Transforming the Neurotoxin Market